# Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

> **NCT00115999** · PHASE3 · COMPLETED · sponsor: **ARCA Biopharma, Inc.** · enrollment: 300 (—)

## Conditions studied

- Arterial Occlusive Diseases

## Interventions

- **DRUG:** alfimeprase

## Key facts

- **NCT ID:** NCT00115999
- **Lead sponsor:** ARCA Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 300 (—)
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115999, "Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00115999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*